Table 3 Death and AIDS Progression among HIV-2 –infected patients in 17 studies
From: Antiretroviral therapy response among HIV-2 infected patients: a systematic review
| Study | Duration on follow up on ART (months) | Crude mortality | Survival | Survival | Survival | Progression to AIDS |
|---|---|---|---|---|---|---|
| (Author, year) | Month 12 | Month 24 | Month 36 | |||
| (%) | ||||||
| Adje-Touré, 2003 [34] | 11 [7–12] | NR | NR | NR | NR | NR |
| Van Der Ende, 2003 [29] | 23 [13–58] | NR | NR | NR | NR | 2/13 (15%) |
| Mullins 2004 [39] | 22 [8 – 35] | NR | 100% | NR | NR | NR |
| Matheron, 2006 [40] | 21 | 5/61 (15.8%) | NR | NR | NR | 3/61 (4.9%) |
| Ndour, 2006 [41] | 10 [1–21] | NR | NR | NR | NR | NR* (opportunistic infections 9/35) |
| Drylewicz, 2008 [12] | NR | NR | NR | NR | NR | NR |
| Ruelle 2008 [42] | NR | NR | NR | NR | NR | NR |
| Benard A, 2009 [28] | 26 [10–33] | 2/29 (6.9%) | NR | NR | NR | NR |
| Jallow, 2009 [31] | NR | NR | NR | NR | NR | NR |
| Gottlieb, 2009 [23] | 17 [4–55] | NR | NR | NR | NR | NR |
| Harries, 2010 [17] | 23 [8–34] | 14/91 (15.4%) | NR | NR | NR | NR |
| Drylewicz 2010 [30] | 11 [6–13] | 3/270 (1%) | NR | NR | NR | NR |
| Smith 2010 [43] | 13 [0–40] | 7/74 (9.5%) | NR | NR | NR | 24 HIV-AIDS related events |
| Chiara, 2010 [44] | 36 | 0/25 (0.0) | NR | NR | NR | NR |
| Peterson 2011 [18] | 20 [10–33] | 6/51 (11.8%) | 96% | 89% | 80% | NR |
| (89–100) | (76–100) | (58–100) | ||||
| Benard, 2011 [15] | 20 [8–36] | 0/170 (0%) | NR | NR | NR | Yes (n = 10) |
| During the first 12 months | 1/44 (2%) 3 NRTIs | |||||
| 9/126 (7%): PI regimen | ||||||
| Peterson K, 2012 [45] | NR | NR | NR | NR | NR | NR |